Esco Aster is a contract development and manufacturing organisation (CDMO) focusing on offering vaccine, biocell and gene-therapy development manufacturing services using primarily its proprietary Adherent Tide Motion Platform. This is the second Esco Aster collaborative research unit set up globally after the first Centre of Excellence (COE) with Bioprocessing Technology Institute (BTI), Singapore. Esco Aster hopes to continue to develop more collaborations in Asia Pacific in years to come to work on the booming cell and gene therapy.
“One of the focus areas for MAHE is to build and sustain relationship with corporates to promote corporate affiliate research programmes. “I am hopeful that MAHE-Esco Aster partnership will be mutually rewarding and will lead to many more corporate research units to be established at MAHE,” said Dr Raviraja N S, MAHE’s director, corporate relations and professor, Pharmaceutical Biotechnology.
“We look forward to harnessing the skilled manpower and mentor pool available at MAHE to build our pipeline products and services to our clients. We envision showcasing this research unit to our potential clients and collaborators and also utilizing it as a training centre.” said, Xiangliang Lin, CEO, Esco Aster-
Dr Narayana Sabhahit, registrar, MAHE said, “We will recruit skilled manpower to the research unit to execute research projects jointly developed. Esco Aster has agreed to provide all necessary training and equipment to carry out advanced research. They will send trained manpower from Singapore from time to time”.